Ultivue
Ultivue, Inc.: Pioneering commercial physical and biological research since 2015.
Founded
2015Ultivue, Inc.: Pioneering commercial physical and biological research since 2015.
Founded in 2015, Ultivue, Inc. is dedicated to advancing commercial physical and biological research. The company's core mission is to empower scientists in the development of precision cancer therapies through innovative technologies. Ultivue offers ultrasensitive InSituPlex® assays and AI-driven spatial analysis tools that enable rapid, high-confidence insights into tissue samples. Their primary market focus is on providing solutions for profiling the immune landscape in tissues, thereby turning complex biological data into actionable insights.
Notable figures affiliated with Ultivue include leading scientists and industry experts who contribute to its pioneering research and development efforts. The company has attracted significant investment from prominent venture capital firms, bolstering its growth and innovation capacity. Key achievements include the successful deployment of InSituPlex® technology in numerous research settings, significantly accelerating the pace of cancer therapy development. Ultivue's impact is evident in its ability to provide researchers with unprecedented clarity and speed in biomarker analysis, ultimately enhancing the precision and effectiveness of cancer treatments.
Companies similar to Ultivue include SpIntellx, TenSixty Biosciences, Novasenta and PredxBio.
Ultivue was founded in 2015.
Ultivue's headquarters is located in Cambridge, MA, US.
Ultivue's most recent funding round was for $50M (USD) in April 2021.
As of Apr 27, 2021, Ultivue has disclosed funding of $107.3M (USD). Undisclosed round amounts are excluded.
Ultivue has 56 employees as of Feb 5, 2024.
PredxBio
predxbio.com
